Furthermore, while longer OS and a higher ORR were observed with nivolumab plus ipilimumab than with sunitinib across tumor PD-L1 expression levels, the magnitude of benefit was higher in the population with 1% or greater PD-L1 expression [7]. Here, CD274 is linked to neoplasm.